Craig, H. C. http://orcid.org/0000-0002-7288-5245
Alsaeed, D.
Heneghan, H.
Al-Najim, W. http://orcid.org/0000-0002-0020-4391
Al Ozairi, E. http://orcid.org/0000-0001-5006-4369
le Roux, C. W. http://orcid.org/0000-0001-5521-5445
Article History
Received: 21 December 2023
Revised: 13 April 2024
Accepted: 17 April 2024
First Online: 1 May 2024
Competing interests
: HCC, Part funding of PhD tuition fees from the Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (SOPHIA) project (). WAl-N—no conflict of interest. DA—no conflict of interest. HH—no conflict of interest. EAO—no conflict of interest, CWlR: Consulting fees/Honoria/Support for meetings: NovoNordisk, Eli Lilly, Johnson & Johnson, Boehringer Ingelheim, GI Dynamics, Herbalife. Leadership/fiduciary role in Board: Irish Society for Nutrition and Metabolism (unpaid). Stock Options: Keyron Previous Chief medical officer and Director of the Medical Device Division of Keyron in 2011. Both of these were unremunerated positions. Previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. He continues to provide scientific advice to Keyron for no remuneration.